A Pilot Study of Perioperative Nivolumab and Paricalcitol to Target the Micoenvironment in Resectable Pancreatic Cancer
Status:
Recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to look at the potential effects of paricalcitol (a drug
similar to vitamin D) and nivolumab on pancreatic tumors in patients who are treated with
gemcitabine and abraxane. The study will also look at the safety of including paricalcitol
and nivolumab as part of the gemcitabine and abraxane chemotherapeutic regimen.
Phase:
Early Phase 1
Details
Lead Sponsor:
Abramson Cancer Center of the University of Pennsylvania